Cargando…

Image-Guided Ablation Therapies for Extrahepatic Metastases from Hepatocellular Carcinoma: A Review

SIMPLE SUMMARY: Although systemic therapies are a common treatment for patients with extrahepatic metastases from hepatocellular carcinoma (HCC), local ablative therapies, such as radiofrequency ablation, microwave ablation, and cryoablation, can be used in select patients who have metastases to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Umakoshi, Noriyuki, Matsui, Yusuke, Tomita, Koji, Uka, Mayu, Kawabata, Takahiro, Iguchi, Toshihiro, Hiraki, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378118/
https://www.ncbi.nlm.nih.gov/pubmed/37509326
http://dx.doi.org/10.3390/cancers15143665
Descripción
Sumario:SIMPLE SUMMARY: Although systemic therapies are a common treatment for patients with extrahepatic metastases from hepatocellular carcinoma (HCC), local ablative therapies, such as radiofrequency ablation, microwave ablation, and cryoablation, can be used in select patients who have metastases to the lung, bone, and other sites with curative or palliative intent. This review summarizes the currently available evidence on image-guided thermal ablation therapies for extrahepatic metastases from HCC. ABSTRACT: The most common sites of extrahepatic metastases from hepatocellular carcinoma (HCC) are the lungs, intra-abdominal lymph nodes, bones, and adrenal glands, in that order. Although systemic therapies are a common treatment for patients with extrahepatic metastases, local ablative therapies for the extrahepatic metastatic lesions can be performed in selected patients. In this article, the literature on image-guided thermal ablation for metastasis to each organ was reviewed to summarize the current evidence. Radiofrequency ablation was the most commonly evaluated technique, and microwave ablation, cryoablation, and percutaneous ethanol injection were also utilized. The local control rate of thermal ablation therapy was relatively favorable, at approximately 70–90% in various organs. The survival outcomes varied among the studies, and several studies reported that the absence of viable intrahepatic lesions was associated with improved survival rates. Since only retrospective data from relatively small studies has been available thus far, more robust studies with prospective designs and larger cohorts are desired to prove the usefulness of thermal ablation for extrahepatic metastases from HCC.